ArticleNeurology2020
Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke.
Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Stroke risk after varicella-zoster virus infection: a systematic review and meta-analysis.Journal of neurovirology · 2023Pooled it
- Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Beyond the Virological Benefits of the Herpes Zoster Vaccine in the Context of Primary Care.Vaccines · 2026Article
- Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection.The Journal of infectious diseases · 2025Article
- Article
- Viral Infection and Ischemic Stroke: Emerging Trends and Mechanistic Insights.Journal of the American Heart Association · 2024Review
- New Directions in Infection-Associated Ischemic Stroke.Journal of clinical neurology (Seoul, Korea) · 2024Review
- Article
- Common Features Between Stroke Following Varicella in Children and Stroke Following Herpes Zoster in Adults : Varicella-Zoster Virus in Trigeminal Ganglion.Current topics in microbiology and immunology · 2023Review
- COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older: Self-Controlled Case Series Study.Neurology · 2022Article
- An Insight into Biomolecules for the Treatment of Skin Infectious Diseases.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine whether increased risk of acute ischemic stroke (AIS) following herpes zoster (HZ) might be modified by the status of zoster vaccine live (ZVL) vaccination and antiviral treatment following HZ.
methodsWe included 87,405 Medicare fee-for-service beneficiaries aged ≥66 years diagnosed with HZ and AIS from 2008 to 2017. We used a self-controlled case series design to examine the association between HZ and AIS, and estimated incidence rate ratios (IRRs) by comparing incidence of AIS in risk periods vs control periods. To examine effect modification by ZVL and antiviral treatment, beneficiaries were classified into 4 mutually exclusive groups: (1) no vaccination and no antiviral treatment; (2) vaccination only; (3) antiviral treatment only; and (4) both vaccination and antiviral treatment. We tested for interaction to examine changes in IRRs across 4 groups.
resultsAmong 87,405 beneficiaries with HZ and AIS, 22.0%, 2.0%, 70.1%, and 5.8% were in groups 1 to 4, respectively. IRRs in 0-14, 15-30, 31-90, and 91-180 days following HZ were 1.89 (95% confidence interval [CI], 1.77-2.02), 1.58 (95% CI, 1.47-1.69), 1.36 (95% CI, 1.31-1.42), and 1.19 (95% CI, 1.15-1.23), respectively. There was no evidence of effect modification by ZVL and antiviral treatment on AIS (
conclusionsRisk of AIS increased significantly following HZ, and this increased risk was not modified by ZVL and antiviral treatment. Our findings suggest the importance of following recommended HZ vaccination in prevention of HZ and HZ-associated AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.